Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating CNTO328 (siltuximab) plus best supportive care for multicentric Castleman's disease has completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multicentric Castleman Disease

Drugs mentioned

• CNTO328 (siltuximab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multicentric Castleman's Disease | Phase 2 | Status: COMPLETED | Results posted: 2014-08-20